BioSpace News Archive

Group K Diagnostics announced today the appointment of Dr. Jay Rosan to the board of directors.

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime Standard: VSC), today announced the signing of an agreement under which Immunic will settle its remaining obligation of a 4.4% royalty on net sales of selective oral DHODH inhibitor, IMU-838, for $17.25 million

Evive Biotech, a global biologics company developing novel biologic therapies, today announced the submission of its Biologics License Application (BLA) for Ryzneuta™ (also known as F-627) to the US Food & Drug Administration (FDA

Imaging Endpoints (IE) announced today that it has formally established Research Endpoints, LLC, as a new wholly-owned subsidiary to manage the extraordinary demand for its exploratory imaging research and biomarker discovery business.

Research firm predicts future growth in market to be accelerated by affordable, easy-to-deploy, scalable solutions like Sickbay

InterSystems, a creative data technology provider dedicated to helping customers solve the most critical scalability, interoperability, and speed problems, today announced its membership in the Vulcan FHIR® ACCELERATOR™ Program, a new multi-stakeholder initiative launched by Health Level Seven® International (HL7®) to empower clinical researchers with greater interoperability.

Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, announced today that Alicia Secor, president and chief executive officer, and Aimee L. Jackson, Ph.D., chief scientific officer, are scheduled to participate virtually in an analyst-led fireside chat at the Stifel 3rd Annual CNS Day on Thursday, April 1, 2021 at 1:30 pm ET.

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, and Tesis Labs, a US multi-region lab services provider with labs in Colorado, Texas and Arizona, announced a strategic partnership in the field of prenatal genetic testing.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today it is initiating a Dose Response in-vivo Study in mice; results to be included as part of the Product Package to be submitted to the U.S. Food and Drug Administration

The CEO of Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, appeared yesterday on Yahoo!